Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.3621 http://scihub22266oqcxt.onion/10.18632/oncotarget.3621 C4558128!4558128 !25879451     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25879451 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Oncotarget 2015 ; 6 (17 ): 14953-69 Nephropedia Template TP {{tp|p=25879451 |t=2015. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms |pdf=|usr=}}{{25879451 }} gab.com Text Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=25879451 #FOAvip The T-cell lymphoproliferative neoplasms (T-LPN) are characterized by a poor clinical outcome. Current therapeutics are mostly non-selective and may induce harmful side effects. It has been reported that NOTCH1 activation mutations frequently associate T-LPN. Because anti-Notch1 based therapies such as ?-secretase inhibitors (GSI) are less efficient and induce considerable side effects, we hypothesized that combining low concentrations of GSI and the proteasome inhibitor bortezomib (BTZ) may provide an effective and tolerable approach to treat T-LPN. Hence, we analyzed the in vitro and in vivo effects of GSI-I and BTZ, alone or in combination, against T-LPN. GSI-I and BTZ synergistically decreased cell viability, proliferation, and colony formation, and induced apoptosis in T-LPN cell lines. Furthermore, combining GSI-I and BTZ decreased the viability of primary T-LPN cells from patients. These effects were accompanied by deregulation of Notch1, AKT, ERK, JNK, p38 MAPK, and NF-?B survival pathways. Moreover, combination treatment inhibited T-LPN tumor growth in nude mice. In all experiments, combining low concentrations of GSI-I and BTZ was superior to using a single agent. Our data support that a synergistic antitumor activity exists between GSI-I and BTZ, and provide a rationale for successful utilization of dual Notch1 and proteasome inhibition to treat T-LPN. Twit Text FOAVip Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=25879451 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25879451 #FOAvip English Wikipedia <ref>{{Cite pmid|25879451 }}</ref> Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms #MMPMID25879451 Yang L ; Zhang S ; George SK ; Teng R ; You X ; Xu M ; Liu H ; Sun X ; Amin HM ; Shi W Oncotarget 2015[Jun]; 6 (17 ): 14953-69 PMID25879451 show ga The T-cell lymphoproliferative neoplasms (T-LPN) are characterized by a poor clinical outcome. Current therapeutics are mostly non-selective and may induce harmful side effects. It has been reported that NOTCH1 activation mutations frequently associate T-LPN. Because anti-Notch1 based therapies such as ?-secretase inhibitors (GSI) are less efficient and induce considerable side effects, we hypothesized that combining low concentrations of GSI and the proteasome inhibitor bortezomib (BTZ) may provide an effective and tolerable approach to treat T-LPN. Hence, we analyzed the in vitro and in vivo effects of GSI-I and BTZ, alone or in combination, against T-LPN. GSI-I and BTZ synergistically decreased cell viability, proliferation, and colony formation, and induced apoptosis in T-LPN cell lines. Furthermore, combining GSI-I and BTZ decreased the viability of primary T-LPN cells from patients. These effects were accompanied by deregulation of Notch1, AKT, ERK, JNK, p38 MAPK, and NF-?B survival pathways. Moreover, combination treatment inhibited T-LPN tumor growth in nude mice. In all experiments, combining low concentrations of GSI-I and BTZ was superior to using a single agent. Our data support that a synergistic antitumor activity exists between GSI-I and BTZ, and provide a rationale for successful utilization of dual Notch1 and proteasome inhibition to treat T-LPN. |Adult [MESH] |Aged [MESH] |Amyloid Precursor Protein Secretases/*antagonists & inhibitors [MESH] |Animals [MESH] |Antineoplastic Combined Chemotherapy Protocols/*pharmacology [MESH] |Apoptosis/drug effects [MESH] |Blotting, Western [MESH] |Bortezomib/administration & dosage/*pharmacology [MESH] |Cell Line, Tumor [MESH] |Cell Proliferation/drug effects [MESH] |Drug Synergism [MESH] |Female [MESH] |Humans [MESH] |Jurkat Cells [MESH] |Leukemia, T-Cell/*drug therapy/metabolism/pathology [MESH] |Lymphoma, T-Cell/metabolism/pathology [MESH] |Male [MESH] |Mice, Nude [MESH] |Oligopeptides/administration & dosage/*pharmacology [MESH] |Proteasome Endopeptidase Complex/*metabolism [MESH] |Proteasome Inhibitors/administration & dosage/pharmacology [MESH] |Receptor, Notch1/*antagonists & inhibitors [MESH] |Tumor Cells, Cultured [MESH] |Xenograft Model Antitumor Assays [MESH]Targeting Notch1 and proteasome as an effective strategy to suppress T(epmc).pdf DeepDyve Pubget Overpricing